Pneumococcal vaccination in adult patients with comorbidities: a review of the clinical practice guidelines

Clinical Microbiology and Antimicrobial Chemotherapy. 2020; 22(4):254-265

​ Kozlov R.S., Andreeva I.V., Stetsiouk O.U., Muravyev A.A.
10.36488/cmac.2020.4.254-265
clinical practice guidelines pneumococcal infection Streptococcus pneumoniae pneumococcal vaccines
Section
Diseases and Pathogens
Type
Review
Publication
Clinical Microbiology and Antimicrobial Chemotherapy. 2020; 22(4):254-265

Abstract

The review discusses national clinical practice guidelines for pneumococcal vaccination in different countries, existing approaches to adult immunization, and highlights key results of the most significant clinical studies and metaanalyses on the effectiveness of 23-valent polysaccharide pneumococcal vaccine and 13-valent conjugated pneumococcal vaccine in adults, including the elderly and patients with comorbidities.

Roman S. Kozlov

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Irina V. Andreeva

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Olga U. Stetsiouk

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

Alexander A. Muravyev

Institute of Antimicrobial Chemotherapy, Smolensk, Russia

  • 1. Berg A.O., Atkins D., Tierney W. Clinical practice guidelines in practice and education. J Gen Intern Med. 1997;12(Suppl. 2):S25-33. DOI: 10.1046/j.15251497.12.s2.4.x
  • 2. Field M.J., Lohr K.N. (Eds). Clinical Practice Guidelines: Directions for a New Program, Institute of Medicine, Washington, DC: National Academy Press, 1990.
  • 3. Kovaleva M.Yu., Sukhorukikh O.A. Clinical guidelines. History of the creation and development in the Russian Federation and abroad. Remedium Privolzh'e. Journal about the Russian market of medicines and medical equipment. 2019;(5-5):2-8. Russian. DOI: 10.21518/1561-5936-2019-1-2-6-14
  • 4. Federal Law 25.12.2018 N 489-FZ «On Amendments to Article 40 of the Federal Law “On obligatory medical insurance in the Russian Federation” and the Federal Law «On the Fundamentals of Health Protection of Citizens in the Russian Federation» on clinical guidelines» Available at: https://base.garant.ru/72136974/. Accessed January 18, 2021. Russian.
  • 5. Methodological guidelines «Vaccination of patients after auto- and allo-HSCT», 2019. Available at: http://democenter.nitrosbase.com/clinrecalg5/static/ПР17.PDF. Accessed January 18, 2021. Russian.
  • 6. Methodical recommendations for the detection, investigation and prevention of adverse events after immunization (approved by the Ministry of Health of Russia on April 12, 2019). Moscow, 2019. 56 p. Russian.
  • 7. Andreeva I.V., Stetsiouk O.U., Kozlov R.S. Current approaches to the specific prevention of pneumococcal infection: Whom, when, what? Jepidemiologija i infekcionnye bolezni. 2015,5:44-57. Russian.
  • 8. Baranov A.A., Namazova-Baranova L.S., Brico N.I., Lobzin Y.V., Коzlov R.S., Kostinov M.P., et al. Vaccinal prevention of pneumococcal infection in children. Pediatricheskaja farmakologija. 2018;15(3):200-211. Russian. DOI: 10.15690/pf.v15i3.1899
  • 9. Kozlov R.S., Avdeev S.N., Briko N.I., Bilichenko T.N., Kostinov M.P., Sidorenko S.V., et al. Vaccination against pneumococcal infections in adults Resolution of the expert council (Moscow, 16 December 2017). Klinicheskaja mikrobiologija i antimikrobnaja himioterapija. 2018;1: 5-8. Russian. DOI: 10.36488/cmac.2018.1.5-8
  • 10. Rudakova A.V., Briko N.I., Lobzin Yu.V., NamazovaBaranova L.S., Avdeev S.N., Ignatova G.L., et al. Vaccination-against pneumococcal infections in Russian Federation: social and pharmacoeconomic aspects. Zhurnal infektologii. 2018;10(3):11-22. Russian. DOI: 10.22625/2072-6732-2018-10-3-11-22
  • 11. Chuchalin A.G., Briko N.I., Avdeev S.N., Belevskiy A.S., Bilichenko T.N., et al. Federal clinical guidelines on preventive vaccination against pneumococcal infections in adults. Russian Pul'monologija. 2019;29(1):19-34. Russian. DOI: 10.18093/0869-0189-2019-29-1-19-34
  • 12. Moberley S., Holden J., Tatham D.P., Andrews R.M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;2013(1):CD000422. DOI: 10.1002/14651858.CD000422.pub3
  • 13. Kraicer-Melamed H., O'Donnell S., Quach C. The effectiveness of pneumococcal polysaccharide vaccine 23 (PPV23) in the general population of 50 years of age and older: A systematic review and meta-analysis. Vaccine. 2016;34(13):1540-1550. DOI: 10.1016/j.vaccine.2016.02.024
  • 14. Falkenhorst G., Remschmidt C., Harder T., HummersPradier E., Wichmann O., Bogdan C. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against pneumococcal disease in the elderly: systematic review and meta-analysis. PLoS One. 2017;12(1):e0169368. DOI: 10.1371/journal.pone.0169368
  • 15. Shimbashi R., Suzuki M., Chang B., Watanabe H., Tanabe Y., Kuronumaet K., et al. Adult IPD Study Group. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in adults, Japan, 2013-2017. Emerg Infect Dis. 2020;26(10):23782386. DOI: 10.3201/eid2610.191531
  • 16. Berild J.D., Winje B.A., Vestrheim D.F., Slotved H.C., Valentiner-Branth P., Roth A., et al. A systematic review of studies published between 2016 and 2019 on the effectiveness and efficacy of pneumococcal vaccination on pneumonia and invasive pneumococcal disease in an elderly population. Pathogens. 2020;9(4):259. DOI: 10.3390/pathogens9040259
  • 17. Bonten M.J., Huijts S.M., Bolkenbaas M., Webber C., Patterson S., Gault S., et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372:1114-1125. DOI: 10.1056/NEJMoa1408544
  • 18. Lawrence H., Pick H., Baskaran V., Daniel P., Rodrigo C., Ashtonet D., et al. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study. PLoS Med. 2020;17(10):e1003326. DOI: 10.1371/journal.pmed.1003326
  • 19. Bonnave C., Mertens D., Peetermans W., Cobbaert K., Ghesquiere B., Deschodtet M., et al. Adult vaccination for pneumococcal disease: a comparison of the national guidelines in Europe. Eur J Clin Microbiol Infect Dis. 2019;38(4):785-791. DOI: 10.1007/s10096-01903485-3
  • 20. Winje B.A., Berild J.D., Vestrheim D.F., Denison E., Lepp T., Roth A., et al. Efficacy and effectiveness of pneumococcal vaccination in adults – an update of the literature. Norwegian Institute of Public Health, Published 30.12.2019. Available at: https://www.fhi.no/en/publ/2019/efficacyand-effectiveness-of-pneumococcal-vaccination-in-adults--an-updat/. Accessed January 18, 2021.
  • 21. Meeting of the Strategic Advisory Group of Experts on Immunization, October 2020 – conclusions and recommendations. WHO. Wkly Epidemiol Rec. 2020;95(48):585608.
  • 22. Briko N.I. Introduction of mass vaccination against pneumococcal infection in Russia: successes and problems. Report at the 3rd Euro-Asian summit of specialists on pneumococcal infection. August 24-25, 2019. Available at: https://congress-ph.ru/common/htdocs/upload/fm/pnevmokoki/19/prez/1.pdf. Accessed January 18, 2021. Russian.
  • 23. Principles and considerations for adding a vaccine into a national immunization programme: From decision to implementation and monitoring. Geneva: World Health Organization; April 2014. Available at: www.who.int/immunization/programmes_systems/policies_strategies/vaccine_intro_resources/nvi_guidelines/en/. Accessed January 18, 2021.
  • 24. Tomczyk S., Bennett N.M., Stoecker C., Gierke R., Moore M.R., Whitney C.G., et al; Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥ 65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63(37):822-825. PMID: 25233284
  • 25. Matanock A., Lee G., Gierke R., Kobayashi M., Leidner A., Pilishvili T. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep. 2019;68(46):10691075. DOI: 10.15585/mmwr.mm6846a5
  • 26. Freedman M.S., Hunter P., Ault K., Kroger A. Advisory committee on immunization practices recommended immunization schedule for adults aged 19 years or older – United States, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(5):133-135. DOI: 10.15585/mmwr.mm6905a4
  • 27. Kadoglou N.P.E., Parissis J., Seferovic P., Filippatos G. Vaccination in heart failure: an approach to improve outcomes. Rev Esp Cardiol (Engl Ed). 2018;71(9):697699. English, Spanish. DOI: 10.1016/j.rec.2018.02.012
  • 28. Ren S., Newby D., Li S.C., Walkom E., Miller P., Hure A., et al. Effect of the adult pneumococcal polysaccharide vaccine on cardiovascular disease: a systematic review and meta-analysis. Open Heart. 2015;2(1):e000247. DOI: 10.1136/openhrt-2015-000247
  • 29. Marra F., Zhang A., Gillman E., Bessai K., Parhar K., Vadlamudi N.K., et al. The protective effect of pneumococcal vaccination on cardiovascular disease in adults: A systematic review and meta-analysis. Int J Infect Dis. 2020;99:204213. DOI: 10.1016/j.ijid.2020.07.038
  • 30. Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G., Coats A.J., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975. DOI: 10.1002/ejhf.592
  • 31. Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E.Jr., Drazneret M.H., et al. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147239. DOI: 10.1016/j.jacc.2013.05.019
  • 32. Heart Failure Society of America, Lindenfeld J., Albert N.M., Boehmer J.P., Collins S.P., Ezekowitz J.A., Givertzet M.M., et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2010;16(6):e1-194. DOI: 10.1016/j.cardfail.2010.04.004
  • 33. American Diabetes Association. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl. 1):S37-S47. DOI: 10.2337/dc20-S004
  • 34. Diabetes Canada Clinical Practice Guidelines Expert Committee, Husein N., Chetty A. Influenza, pneumococcal, hepatitis B and Herpes Zoster vaccinations. Can J Diabetes. 2018;42(Suppl. 1):S142-S144. DOI: 10.1016/j.jcjd.2017.10.016
  • 35. Kobayashi M., Bennett N.M., Gierke R., Almendares O., Moore M.R., Whitney C.G., et al. Intervals between PCV13 and PPSV23 vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2015;64:944-947. DOI: 10.15585/mmwr.mm6434a4
  • 36. Meroni P.L., Zavaglia D., Girmenia C. Vaccinations in adults with rheumatoid arthritis in an era of new diseasemodifying anti-rheumatic drugs. Clin Exp Rheumatol. 2018;36(2):317-328. PMID: 29303710
  • 37. Furer V., Rondaan C., Heijstek M.W., Agmon-Levin N., van Assen S., Bijlet M., et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39-52. DOI: 10.1136/annrheumdis-2019-215882
  • 38. Shea K.M., Edelsberg J., Weycker D., Farkouh R.A., Strutton D.R., Pelton S.I. Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis. 2014;1(1):ofu024. DOI: 10.1093/ofid/ofu024
  • 39. Rubin L.G., Levin M.J., Ljungman P., Davies E.G., Avery R., Tomblyn M., et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:e44-e100. DOI: 10.1093/cid/cit816
  • 40. Kim D.K., Hunter P. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older – United States, 2019. MMWR Morb Mortal Wkly Rep. 2019;68:115-118. DOI: 10.15585/mmwr.mm6805a5
  • 41. Rhee Y., Sha B.E., Santos C.A.Q. Optimizing vaccination in adult patients with liver disease and liver transplantation. Clin Liver Dis (Hoboken). 2020;15(2):63-68. DOI: 10.1002/cld.898
  • 42. Walters J.A., Tang J.N., Poole P., Wood-Baker R. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017;1(1):CD001390. DOI: 10.1002/14651858.CD001390.pub4
  • 43. Singh D., Agusti A., Anzueto A., Barnes P.J., Bourbeau J., Bartolome R., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164. DOI: 10.1183/13993003.00164-2019
  • 44. Community-acquired pneumonia (clinical guidelines, draft version), 2018. Available at: www.antibiotic.ru/files/docs/vpproject-20181028.docx. Accessed January 17, 2021. Russian.
  • 45. Chronic Obstructive Lung Disease (clinical guidelines), 2018. Available at: http://cr.rosminzdrav.ru/recomend/603. Accessed January 18, 2021. Russian.
  • 46. Chronic heart failure (clinical guidelines), 2020. Available at: http://cr.rosminzdrav.ru/recomend/156. Accessed January 18, 2021. Russian.
  • 47. Vaccination against pneumococcal infection in children (Guidance on the prevention of disease/syndrome), 2018. Available at: http://democenter.nitrosbase.com/clinrecalg5/static/ПР4.PDF. Accessed January 18, 2021. Russian.
Views
0 Abstract
0 PDF
0 Crossref citations
Shared